文献速递生殖医学

高反应人群卵母细胞利用率的影响因素探索

[An exploration of contributing factors to the oocyte utility rate of high responders in an in vitro fertilization cycle].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2021-01-01

该研究定义卵母细胞利用率(OUR)为可移植和/或冻存胚胎数与获卵数的比值,纳入获卵数≥15个的冻胚周期,比较OUR最高10%与最低10%两组。多因素logistic回归显示既往IVF/ICSI史和子宫内膜异位症是OUR的不利因素,双重降调节方案和较长促排卵时间是保护因素,雌二醇下降则降低OUR。

要点

  • 既往IVF/ICSI史和子宫内膜异位症是高反应人群OUR的独立危险因素。
  • 双重降调节方案和适当延长促排卵时间可能改善OUR。
  • 促排卵期间应避免雌二醇水平下降以保障OUR。

核心结论

  • 高反应人群中既往IVF/ICSI史和子宫内膜异位症是OUR的不利因素。
  • 促排卵时选择双重降调节方案和适当延长刺激时间并避免雌二醇下降可获更佳OUR。

研究设计与样本

  • 回顾性队列研究,纳入2013年1月至2019年12月获卵数≥15个的冻胚周期。
  • 选取OUR最高10%的43例为高OUR组,最低10%的47例为低OUR组。

主要发现

  • 高OUR组OUR为77.4%(601/776),低OUR组为11.9%(104/874)。
  • 既往IVF/ICSI史OR=0.10(95%CI 0.01~0.81),子宫内膜异位症OR=0.16(95%CI 0.03~0.84),雌二醇下降OR=0.16(95%CI 0.04~0.64)。
  • 双重降调节方案OR=3.74(95%CI 1.06~26.86),较长促排卵时间OR=3.24(95%CI 1.25~8.42)。
  • 高OUR组累积临床妊娠率95.3%(41/43)vs 40.4%(19/47),累积活产率90.7%(39/43)vs 31.9%(15/47),P均<0.01。

临床怎么用

  • 对高反应人群促排卵前评估既往IVF/ICSI史和子宫内膜异位症,可考虑双重降调节方案。
  • 促排卵中适当延长刺激时间并监测雌二醇,避免其水平下降。

局限性

  • 回顾性研究,样本量较小(高OUR组43例,低OUR组47例)。
  • 仅纳入获卵数≥15个的冻胚周期,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To figure out the clinical factors contributing to the oocytes utility rate (OUR) of high responders in in vitro fertilization (IVF)-embryo transfer treatment. Methods: OUR was defined by the number of usable embryos for transfer and (or) cryopreservation divided by the number of oocytes retrieved in a freeze-all cycle. The cycles with ≥15 eggs were included from January 2013 to December 2019. Those with OUR at the top 10% (Group A) and the bottom 10% (Group B) were picked and compared for patients' characteristics, parameters relating to ovary stimulation and pregnant outcomes. Multifactorial logistic regression was applied to reveal the risk factors affecting OUR in them. Results: A total of 43 patients were included in Group A (OUR: 77.4%, 601/776) and 47 for Group B (OUR: 11.9%, 104/874). Previous IVF/intracytoplasmic sperm injection (ICSI; OR=0.10, 95%CI: 0.01-0.81) and endometriosis (OR=0.16, 95%CI: 0.03-0.84) were negative factors for OUR (P<0.05); dual suppression protocol (OR=3.74, 95%CI: 1.06-26.86) and longer days of stimulation (OR=3.24, 95%CI: 1.25-8.42) were protective factors in terms of ovarian stimulation (P<0.05), on contrary to that, any decline of estradiol during the stimulation led to poorer OUR (OR=0.16, 95%CI: 0.04-0.64). Although two groups had similar quantities of eggs and metaphase of meiosis Ⅱ (MⅡ) oocytes, distinguished cumulative clinical pregnancy rate and cumulative live birth rate were seen in Group A and group B respectively [95.3% (41/43) vs 40.4% (19/47) and 90.7% (39/43) vs 31.9% (15/47), all P<0.01]. Conclusions: High responders with attempted IVF/ICSI and endometriosis should be considered as risk factors for OUR. Over ovarian stimulation, dual suppression and a slightly longer stimulating duration could be tried; besides, estradiol decline should be prevented for a better OUR. 目的: 探索影响体外受精(IVF)-胚胎移植治疗中高反应人群卵母细胞利用率(OUR)的临床因素。 方法: OUR的定义为可移植和(或)可冻存的卵裂期胚胎和(或)囊胚的数量与当个周期获卵数的比值。选取中国医学科学院北京协和医院2013年1月至2019年12月期间获卵数≥15个的周期,将OUR位于最高与最低10%的周期分为高OUR组和低OUR组,比较两组患者的一般情况、促排卵治疗的相关参数和妊娠结局,采用多因素logistic回归分析影响高反应人群OUR的临床因素。 结果: 高OUR组纳入了43例患者,低OUR组纳入了47例患者,两组的OUR分别为77.4%(601/776)和11.9%(104/874)。既往IVF或卵母细胞胞质内单精子注射(IVF/ICSI)史(OR=0.10,95%CI为0.01~0.81)、不孕因素为子宫内膜异位症(OR=0.16,95%CI为0.03~0.84)以及卵巢刺激期间雌二醇水平下降(OR=0.16,95%CI为0.04~0.64)是OUR的不利因素(P<0.05);在促排卵方面,双重降调节方案(OR=3.74,95%CI为1.06~26.86)和相对长的促排卵时间(OR=3.24,95%CI为1.25~8.42)是获得较高OUR的保护性因素(P<0.05)。虽然两组患者的获卵数及第二次减数分裂中期的卵母细胞(MⅡ)数相似,但高OUR组的累积临床妊娠率和累积活产率[分别为95.3%(41/43)、90.7%(39/43)]均显著高于低OUR组[分别为40.4%%(19/47)、31.9%(15/47)],两组分别比较,差异均有统计学意义(P均<0.01)。 结论: 在高反应人群中,既往IVF/ICSI治疗史不利于OUR,促排卵时,可尽量选择双重降调节方案和适当延长促排卵时间并避免雌激素水平的下降,以保证更佳的OUR。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang DD, Zhen JR, Yu Q, et al. [An exploration of contributing factors to the oocyte utility rate of high responders in an in vitro fertilization cycle]. Zhonghua Fu Chan Ke Za Zhi. 2021. PMID: 33874713. doi:10.3760/cma.j.cn112141-20200723-00597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。